Producing engineered extracellular vesicles with a platform approach
Feb
13
2025
On demand

Producing engineered extracellular vesicles with a platform approach

Thursday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Sponsor
Producing engineered extracellular vesicles with a platform approach

Extracellular Vesicles (EVs), including exosomes, are emerging as promising natural nano-scale platforms for delivering gene therapies.

In this webinar, we'll discuss materials and methods to enable the expression of biomolecules on EVs. Data will be shared for using protein scaffolds, such as PTGFRN and BASP-1, that are clinically proven to effectively load therapeutic proteins on the surface or lumen of EVs. Chemical linkers were developed to link nucleic acids or small molecules to the EV membrane while preserving their bioactivity and potency. We will also present case study clinical-stage data and further platform developments.

  • Learn why EVs including exosomes are a promising modality to deliver therapeutic payload with an excellent safety profile
  • Find out how novel linking and loading technologies can enable the precision engineering of EVs, through case study examples and clinical stage data
  • See clinical data for therapeutics that have completed Phase 1 studies within oncology applications, including exoSTING™, exoASO-STAT6™, and exoIL-12™
  • Platforms and related clinical assets described here were acquired from Codiak Biosciences and are now available to pharma, biotech, and academic communities
Sriram Sathy
Sriram Sathy
Chief Scientific Officer at AIRNA Biotechnology

Sriram Sathy, PhD is the Chief Scientific Officer at AIRNA Biotechnology and a former CSO at Codiak Biosciences, with over 31 years of experience in genetic medicine, cancer biology, immunology, and neuroscience. He is an accomplished drug developer who has advanced numerous therapeutic candidates, including antibodies, engineered exosomes, and antisense oligonucleotides, from concept to clinical trials.

At Codiak, Dr Sathy led the preclinical evaluation of first-in-class engineered exosome therapeutic programs such as exoIL-12™, exoSTING™, and exoASO™-STAT6, which target cancers including cutaneous T-cell lymphoma and hepatocellular carcinoma. Prior to this, he served as Senior Director at Jounce Therapeutics, where he built translational platforms and biomarker strategies for immunotherapy programs like Vopratelimab. Earlier in his career at Merck Research Laboratories, he focused on translational oncology for biologics.

Dr Sathy earned his PhD in Molecular and Cell Biology from the Indian Institute of Science, Bangalore, and completed postdoctoral research at the University of Pennsylvania, focusing on the genetics of circadian rhythms. A prolific scientist, he has authored 32 peer-reviewed publications and holds multiple patents. Based in Lexington, MA, Dr. Sathy enjoys long-distance biking and is a passionate advocate for cancer research.

Vijetha Bhat
Vijetha Bhat
CGT Technical Expert at Lonza Licensing